Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337002 | 0.91 | MAPT (0.41) | MAPTF9F7SMN1; SMN2IKBKB | |
| SCHEMBL335484 | 0.91 | MAPT (0.43) | MAPTF9F7SMN1; SMN2IKBKB | |
| SCHEMBL335303 | 0.89 | MAPT (0.40) | MCHR1KDRTEKMAPTF9 | |
| SCHEMBL335326 | 0.89 | PDE2A (0.44) | MCHR1KDRTEKPDE2AMAPT | |
| SCHEMBL335283 | 0.87 | MAPT (0.37) | MCHR1KDRTEKPDE2AMAPT | |
| SCHEMBL335968 | 0.86 | MAPT (0.41) | MAPTF9F7SMN1; SMN2IKBKB | |
| SCHEMBL336083 | 0.86 | F9 (0.41) | MAPTF9F7SMN1; SMN2IKBKB | |
| SCHEMBL336687 | 0.85 | MAPT (0.39) | MAPTF9F7SMN1; SMN2IKBKB | |
| SCHEMBL335959 | 0.85 | MAPT (0.41) | MAPTF9F7SMN1; SMN2IKBKB | |
| SCHEMBL335375 | 0.85 | KIT (0.45) | MCHR1MAPTSMN1; SMN2ESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | claimed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | MCHR1 4867/4885KDR 4305/4885TEK 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.